Category Archives: Drugs

Canadian generic drugmakers find fault with USMCA

Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, USMCA | Leave a comment

Patient Advocacy Successes in Fight for Medicines

by Fran Quigley, Health & Human Rights Journal | June 26, 2018 Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The … Continue reading

Posted in Access to Medecines, Biologics/Biosimilars, Cancer, Hepatitis C, Uncategorized | Leave a comment

WHO: Proposed work program on “fair price” undermines affordability of medicines

Source: The Third World Network | May 21, 2018 by KM Gopakumar Geneva:  The proposed work program on fair price raises concerns on affordability of medicines. The document was prepared by the Secretariat of the World Health Organization (WHO)for the … Continue reading

Posted in Access to Medecines, Drug prices, Pricing, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

To Lower Drug Costs at Home, Trump Wants Higher Prices Abroad

Source: The New York Times | May 9, 2018 WASHINGTON — President Trump, poised on Friday to unveil his strategy to lower prescription drug prices, has an idea that may not be so popular abroad: Bring down costs at home … Continue reading

Posted in Access to Medecines, Drug prices, Pricing, Uncategorized | Leave a comment

Why the US and pharmaceutical giants want a provision in India’s patent law revoked

Source: Scroll.in | May 02, 2018 India’s patent laws are under attack again. This time, too, the target is a provision not commonly found in patent laws elsewhere. This rule requires patent holders to disclose whether they are working their … Continue reading

Posted in Generics, Indian Patent Law, IPR, Patents | Leave a comment

India joining RCEP trade pact could be disastrous: NITI Aayog

Source: live mint | April 25, 2018 New Delhi: Government think tank NITI Aayog, in a note on free trade agreements (FTAs) and their costs for India, has argued that the country needs to rethink joining the Regional Comprehensive Economic Partnership … Continue reading

Posted in FTA, India, Regional Comprehensive Economic Partnership, Regulation, Trade Agreements | Leave a comment

Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow

Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading

Posted in Access to Medicins, Brazil Patent Reform, Open access, Patent, Regulation | Leave a comment